John Smither Sells 12,000 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) Director John Smither sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total transaction of $34,920.00. Following the sale, the director owned 91,403 shares in the company, valued at $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Genelux Stock Performance

Shares of NASDAQ:GNLX traded up $0.09 during trading hours on Thursday, reaching $2.99. The stock had a trading volume of 195,980 shares, compared to its average volume of 220,434. Genelux Corporation has a 1 year low of $2.29 and a 1 year high of $8.53. The firm’s 50 day moving average is $2.88 and its 200-day moving average is $2.94. The stock has a market capitalization of $134.07 million, a price-to-earnings ratio of -3.52 and a beta of 0.58.

Genelux (NASDAQ:GNLX) last issued its earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Analysts forecast that Genelux Corporation will post -0.8 EPS for the current year.

Institutional Investors Weigh In On Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. Jefferies Financial Group Inc. purchased a new stake in Genelux in the fourth quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new stake in Genelux in the 4th quarter valued at $52,000. Balyasny Asset Management L.P. purchased a new position in Genelux during the 4th quarter worth $94,000. Align Financial LLC purchased a new position in Genelux during the 4th quarter worth $123,000. Finally, Raymond James Financial Inc. raised its holdings in shares of Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after buying an additional 5,333 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Benchmark dropped their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a report on Friday, March 20th. Wall Street Zen lowered shares of Genelux from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Genelux currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.